Want to see GB:GENF full AI Analyst Report?
Top Page
Genflow Biosciences Plc
(LSE:GENF)
Select Model
Select Model
Rating:47Neutral
Price Target:
2.00 p
▼(-2.44% Downside)
Action:Reiterated
Date:08/26/26
The score is held down primarily by very weak financial performance (pre-revenue, ongoing losses, cash burn, and negative equity). Technicals are neutral-to-slightly supportive in the near term, and corporate events provide a positive catalyst backdrop (IP and preclinical/clinical progress plus non-dilutive partnership), but valuation remains difficult to justify using P/E given continued losses.
Positive Factors
IP Protection
Expanding patent coverage around SIRT6 variants, delivery technologies, and indications can strengthen barriers to entry and support future partnering potential as Genflow advances its longevity platform.
Negative Factors
Pre-Revenue Model
The absence of commercial revenue leaves Genflow dependent on research milestones and external financing rather than recurring operating income, making its financial outlook highly sensitive to development success and timing.
Read all positive and negative factors
Positive Factors
Negative Factors
IP Protection
Expanding patent coverage around SIRT6 variants, delivery technologies, and indications can strengthen barriers to entry and support future partnering potential as Genflow advances its longevity platform.
Read all positive factors
Genflow Biosciences Plc (GENF) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£12.32M
Dividend YieldN/A
Average Volume (3M)1.40M
Price to Earnings (P/E)―
Beta (1Y)-0.14
Revenue GrowthN/A
EPS Growth29.79%
CountryUK
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding566,409,800
10 Day Avg. Volume896,228
30 Day Avg. Volume1,400,637
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)-14.33
Price to Sales (P/S)0.00
P/FCF Ratio-5.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Genflow Biosciences Plc Business Overview & Revenue Model
Company Description
Genflow Biosciences plc, together with its subsidiaries, engages in the research and development of gene therapy targeting the upstream biology of aging in the United Kingdom and Belgium. The company operates as a pre-clinical biotechnology compan...
Genflow Biosciences Plc Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
10
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.09K | -1.20K | -1.03K | -130.00 | 0.00 |
| EBITDA | -2.00M | -1.59M | -1.80M | -1.33M | -988.10K |
| Net Income | -1.42M | -1.59M | -1.63M | -1.34M | -988.29K |
Balance Sheet | |||||
| Total Assets | 452.39K | 385.91K | 1.07M | 2.62M | 276.55K |
| Cash, Cash Equivalents and Short-Term Investments | 111.79K | 278.68K | 683.97K | 2.36M | 224.00K |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 1.00M | 788.92K | 345.74K | 250.99K | 221.43K |
| Stockholders Equity | -550.78K | -403.01K | 725.91K | 2.37M | 55.12K |
Cash Flow | |||||
| Free Cash Flow | -1.44M | -1.08M | -1.66M | -1.37M | -747.38K |
| Operating Cash Flow | -1.44M | -1.08M | -1.66M | -1.37M | -747.38K |
| Investing Cash Flow | 0.00 | 0.00 | -2.44K | -2.48K | 198.50K |
| Financing Cash Flow | 1.31M | 656.63K | 0.00 | 3.50M | 783.71K |
Genflow Biosciences Plc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | £2.33M | -3.03 | -89.43% | ― | 91.27% | 60.98% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | £12.32M | -6.40 | 332.06% | ― | ― | 29.79% | |
47 Neutral | £73.55M | -4.36 | -116.21% | ― | 81.46% | -15.88% | |
46 Neutral | £13.01M | -3.75 | -135.35% | ― | 13.42% | 65.63% | |
44 Neutral | £14.71M | -8.16 | -210.32% | ― | -11.43% | 23.40% | |
38 Underperform | £15.46M | -0.29 | -451.74% | ― | 33.37% | 86.41% |
* Healthcare Sector Average
GB:GENF
Genflow Biosciences Plc
2.18
1.26
139.01%
GB:OBD
Oxford BioDynamics
0.12
-0.37
-76.04%
GB:PYC
Physiomics
0.52
0.07
15.73%
GB:FAB
Fusion Antibodies Plc
11.75
-2.75
-18.97%
GB:4BB
4basebio UK Societas
475.00
-380.00
-44.44%
GB:APTA
Aptamer Group Plc
0.38
-0.73
-65.91%
Genflow Biosciences Plc Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Genflow Advances SIRT6 Patent Portfolio to Bolster Longevity Gene Therapy Strategy
Positive
Aug 3, 2026
Genflow Biosciences, a UK-based biotechnology firm specializing in gene therapies for age-related diseases and longevity, is advancing its lead SIRT6-based candidate GF-1002 through preclinical and clinical programs. The company aims to address si...
Business Operations and StrategyExecutive/Board Changes
Genflow advances SIRT6 longevity platform with positive dog data and new partnerships
Positive
Jul 13, 2026
Genflow Biosciences reported that its SIRT6-centric longevity platform is progressing on schedule, highlighted by positive interim data from the SLAB trial in aged beagles showing improved survival, sustained benefits at three months and a favoura...
Business Operations and StrategyShareholder Meetings
Genflow Wins Strong Shareholder Backing for Governance and New Share Scheme
Positive
Jun 29, 2026
Genflow Biosciences reported that shareholders approved all resolutions at its latest Annual General Meeting, signaling broad support for the company’s governance and strategic direction. Investors endorsed the 2025 annual report, directors&...
Business Operations and Strategy
Genflow’s Chair to Spotlight Longevity and RNA Therapeutics at BIO 2026
Positive
Jun 22, 2026
Genflow Biosciences said its independent non-executive chairman, Gad Berdugo, will represent the longevity-focused biotech at the BIO International Convention 2026 in San Diego. He is scheduled to join a panel on RNA therapeutics, examining where ...
Business Operations and Strategy
Genflow to Unveil Key Beagle Longevity Trial Data at Animal Summit 2026
Positive
Jun 17, 2026
Genflow Biosciences will present data from its SLAB (Sarcopenia and Longevity in Aged Beagles) clinical study at the Animal Longevity Summit 2026 in Toronto, highlighting the potential of its centenarian SIRT6 gene therapy to address multiple hall...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Genflow Sets June AGM and Announces Board Change Amid Longevity R&D Push
Neutral
Jun 4, 2026
Genflow Biosciences Plc, a UK-based longevity-focused biotech with operations in Belgium, is developing gene therapies targeting age-related diseases, led by its SIRT6-based candidate GF-1002 and associated clinical programmes in aged dogs and in ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.